Orthopedics is a $63 billion market, the most relationship-driven segment in medical device, and one of the best-compensated careers in sales.

Here is what is happening in it right now.

I spent the vast majority of my device career in orthopedics. I started out selling pins and screws for a company that no longer exists, moved into trauma, then reconstruction and total joints, and eventually landed in sports medicine. It was a natural progression, and looking back, orthopedics was the right segment for me for two reasons.

The first was that orthopedic surgery is a lot like carpentry, and carpentry was something I already understood. I knew what pins, screws, and nails did. Understanding how they worked inside a human body was not much of a leap. All I had to do was learn the anatomy and the pathology, and I was off and running.

The second reason was simpler: I could see the benefit to the patients. Someone broke a bone and the products I was selling helped fix it. The surgeon did the fixing, of course, but the point stands. That is a meaningful thing to be part of.

Orthopedic surgery changes people's lives in a tangible way. A total knee replacement gives someone their mobility back. An ACL repair gets an athlete back on the field. A spinal fusion takes away pain that has defined someone's daily existence for years. The rep who shows up to support those cases is not just delivering a product. They are part of the care team, and the surgeons they work with know it.

That relationship dynamic is what makes orthopedics one of the most coveted segments in medical device, and also one of the more challenging to break into. Surgeons are loyal to the reps they trust. Building a territory takes time, but there is also real opportunity to make an impact early if you put in the work. The rewards, professional and financial, are there for the people who do.

This week we go deep on orthopedics: the market, the sub-segments with the most momentum, what the latest earnings are telling us, and what a career in this space actually looks like from the ground up.

Glad you're here. Let's get into it.

Andy Knapik, Founder

The Modern Med Rep

Orthopedics is a $63 billion global market in 2026, projected to reach $92 billion by 2035. In the U.S. alone, the market sits at roughly $30 billion. It is one of the most established and most rep-dependent segments in medical device, with surgeon relationships that take years to build and are extraordinarily difficult to disrupt once in place. The five dominant players, DePuy Synthes, Stryker, Zimmer Biomet, Smith & Nephew, and Arthrex, collectively hold more than 55% of global market share. Medtronic is significant in spine. Globus Medical, following its merger with NuVasive, is a major force in spinal surgery.

The sub-segments with the most commercial momentum right now.  Orthopedics is not one market. It is a collection of distinct product categories, each with its own growth trajectory, competitive dynamics, and commercial model. Understanding which sub-segments are growing fastest is the starting point for targeting the right career opportunity.

Foot and ankle.  The fastest-growing category in orthopedics, expanding at 7% to 8% annually. Historically underserved relative to hip and knee, foot and ankle is now a strategic priority for Stryker (through Wright Medical), Zimmer Biomet (through Paragon 28), and several PE-backed platforms. The procedures are well-suited to ASCs, the margins are strong, and the rep saturation is lower than total joints. Stryker's commercial launch of the Encompass total ankle system is the most recent signal of how seriously the major players are investing here.

Orthobiologics.  The fastest-growing M&A category in the space. Orthobiologics covers bone grafts, synthetic bone substitutes, growth factors, and cell-based therapies used to support bone healing and tissue regeneration. The category benefits from an aging population, rising obesity rates, and the increasing complexity of spinal and joint reconstruction procedures. Commercial reps in this space sell into orthopedic, spine, and sports medicine customers and often work alongside traditional implant reps as complementary product lines.

Sports medicine and arthroscopy.  One of the most technically demanding and relationship-intensive areas in orthopedics. Arthroscopic procedures for the shoulder, knee, hip, and ankle require reps who can support complex cases, understand anatomy at a clinical level, and build credibility with sports medicine surgeons. Arthrex dominates this space and has built one of the most rep-loyal cultures in device. Smith & Nephew, Stryker, and Zimmer Biomet are all active competitors.

Spine.  Historically the highest-compensated sub-segment in orthopedics, with established reps earning $300,000 to $500,000 or more in total compensation. The spine market is maturing at the procedure level but experiencing significant disruption from robotics and navigation technology. Globus Medical's ExcelsiusGPS platform and Medtronic's Stealth AXiS are both gaining traction. The complexity of spine cases and the length of the surgeon relationship make this one of the harder segments to break into but one of the most financially rewarding for those who do.

The ASC shift and what it means.  The movement of orthopedic procedures out of hospitals and into ambulatory surgery centers is the most structurally significant commercial trend in this segment right now. As we covered in depth in Issue #001, ASCs now host more than 80% of all U.S. surgeries. Stryker's Q2 data showing hip and knee procedures approaching 20% ASC mix is meaningful. For reps, it means two things: understanding ASC economics and purchasing dynamics is no longer optional, and the companies building robotic and navigation platforms specifically for ASC environments are creating the most active new hiring in the segment.

Orthopedic sales is consistently one of the highest-compensated fields in medical device. Here is what the data shows in 2026.

Compensation.  Median total compensation for orthopedic medical device sales representatives sits between $150,000 and $210,000 per year. Experienced reps with established surgeon relationships and strong territory performance can earn $250,000 to $383,000 at the 75th to 90th percentile. Spine reps at the top of the compensation curve earn $300,000 to $500,000 or more. Commission typically represents 40% to 60% of total earnings, which means territory performance directly drives income in a way that most other sales careers do not.

Entry points.  For someone without existing device experience, the most common paths into orthopedic sales are through a distributor rep role, a clinical associate or case coverage position at a manufacturer, or a product specialist role. Clinical associates spend significant time in the OR supporting cases, building the clinical knowledge and surgeon relationships that lead to full territory responsibility. The ramp is real, typically two to four years before top earnings kick in, but the ceiling is among the highest in the industry.

Where the active hiring is right now.  Foot and ankle is generating the most new territory builds as Stryker, Zimmer Biomet, and PE-backed platforms expand. Orthobiologics is seeing significant hiring as M&A activity in that sub-segment creates new commercial infrastructure. Robotics-trained orthopedic reps are in high demand across Stryker (Mako), Zimmer Biomet (ROSA), and Globus Medical (ExcelsiusGPS). The DePuy Synthes spinoff process will generate significant hiring over the next 12 to 24 months as the new standalone entity builds its own commercial team.

What hiring managers are looking for.  Clinical comfort, relationship-building ability, and consistency. Orthopedic hiring managers are not primarily looking for sales experience. They are looking for people who can earn a surgeon's trust, show up at 6 a.m. for a case, stay until the last instrument is cleaned, and do it again the next day without being asked. The best candidates for orthopedic roles come from adjacent clinical environments: surgical technologists, physical therapists, athletic trainers, and nurses who already know the OR and understand surgical workflow. B2B sales experience is valued but secondary to clinical credibility.

The Boston Scientific PFA sheath recall is a good reminder that recalls are not rare events in medical device. They are a routine part of the industry. The FDA receives thousands of medical device recall reports each year across all classes. Class I recalls involve a reasonable probability of serious health consequences. Class II recalls, like the Boston Scientific sheath, involve a risk of temporary or medically reversible adverse consequences. Class III recalls are for violations unlikely to cause harm.

For a device rep, a recall involving one of your products is one of the highest-stakes situations you will face. How you handle it with your clinical customers will define your credibility more than almost anything else you do in the field.

What to do when a recall hits.  The first step is to know before your customers do, or as close to simultaneously as possible. Your company will typically communicate recall information through your sales management chain and via a formal field safety corrective action notice. Read it carefully. Understand the scope: which product, which lot numbers, what the issue is, and what the corrective action is. Your customers will ask all of these questions and you need to be able to answer them without hesitation.

How to communicate it.  Call your key accounts directly. Do not leave it to a letter or email. A surgeon or OR manager who hears about a recall affecting their facility from you personally, before they read about it elsewhere, will remember that you were the one who called. A surgeon who finds out on their own and then hears from you will remember that too. The difference matters. Be direct, factual, and calm. Explain what the issue is, what the risk level is, what products are affected, and what the next steps are. Do not speculate.

What not to do.  Do not minimize the issue to protect the relationship. If a recall involves a product your surgeon uses regularly, pretending it is not serious when it is will damage trust far more than the recall itself. Customers can handle problems. What they cannot handle is being misled by someone they rely on.

The longer view.  Recalls are part of this industry because the products are complex and the standards are high. A company that issues a recall promptly and communicates clearly is demonstrating that the system is working. The reps who handle recalls well become the people their customers call when they have any problem, not just a recall. That is the kind of relationship that generates long-term territory performance.

This week's question comes up constantly in the context of orthopedics specifically:

Have a question? Reply to this email. The best ones make it into the next issue.

QUOTE OF THE WEEK

“The strength of the team is each individual member.

The strength of each member is the team.”

- Phil Jackson